Key result
Pre-ischemic HSVbcl2 gene transfer increases local viable tissue after focal cerebral ischemia in rats.
Answers are grounded in this paper and cite their sources.
BACKGROUND AND PURPOSE: A process resembling programmed cell death appears to contribute to postischemic neuronal loss in several models of stroke. Because the expression of the bcl-2 gene has been shown to rescue neurons from programmed cell death due to other causes, we determined whether it would be similarly neuroprotective in stroke. METHODS: Replication of defective herpes viral vectors that transduce bcl-2 (HSVbcl2) or Escherichia coli lacZ (HSVlac) were injected into two sites in the rat cerebral cortex 24 hours before induction of neocortical focal ischemia by tandem permanent occlusion of the right middle cerebral artery and ipsilateral common carotid artery. Local ischemic damage was determined 24 hours after occlusion by staining with 2% 2,3,5-triphenyltetrazolium chloride. RESULTS: Expression of bcl-2 in cerebral cortex was confirmed by immunohistochemistry in animals injected with the HSVbcl2 expression vector. Viable tissue was significantly increased at the injection sites in HSVbcl2- but not HSVlac-injected animals. The protection observed in the HSVbcl2 animals was localized to the injection sites. CONCLUSIONS: These data indicate that bcl-2 expression protects neurons in vivo from ischemic injury and suggest the feasibility of gene therapy for stroke and perhaps other neurological diseases in which programmed cell death is involved.
No takes yet. Share an insight, caveat, or question.
Linnik et al. (1995) studied Focal cerebral ischemia. Defective herpes simplex virus-1 vector expressing bcl-2 (HSVbcl2) vs. Defective herpes viral vector transducing Escherichia coli lacZ (HSVlac) was evaluated on Local ischemic damage (viable tissue at injection sites) determined by 2% 2,3,5-triphenyltetrazolium chloride staining. Cortical injection of HSVbcl2 vector 24 hours before focal ischemia significantly increased viable tissue at the injection sites at 24 hours post-occlusion compared with control HSVlac vector in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: